In recent trading session, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) saw 0.63 million shares changing hands at last check today with its beta currently measuring 0.72. Company’s recent per share price level of $9.22 trading at $0.32 or 3.60% at last check today assigns it a market valuation of $793.36M. That most recent trading price of SNDX’s stock is at a discount of -171.91% from its 52-week high price of $25.07 and is indicating a premium of 6.94% from its 52-week low price of $8.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.83 million shares which gives us an average trading volume of 2.24 million if we extend that period to 3-months.

For Syndax Pharmaceuticals Inc (SNDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.99 in the current quarter.

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) trade information

Upright in the green today for gaining 3.60%, in the last five days SNDX remained trading in the red while hitting it’s week-highest on Friday, 06/20/25 when the stock touched $9.22 price level, adding 6.11% to its value on the day. Syndax Pharmaceuticals Inc’s shares saw a change of -53.43% in year-to-date performance and have moved -4.85% in past 5-day. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) showed a performance of -7.15% in past 30-days. Number of shares sold short was 22.0 million shares which calculate 9.96 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 35.5 to the stock, which implies a rise of 74.03% to its recent value today. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 41. It follows that stock’s current price would drop -95.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -95.23% for stock’s current value.

Syndax Pharmaceuticals Inc (SNDX) estimates and forecasts

This year revenue growth is estimated to rise 422.20% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 27.01M for the same. And 10 analysts are in estimates of company making revenue of 33.46M in the next quarter. Company posted 3.5M and 12.5M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.16% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -1.15% while estimates for its earnings growth in next 5 years are of 27.52%.

Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s Major holders

Insiders are in possession of 1.30% of company’s total shares while institution are holding 120.79 percent of that, with stock having share float percentage of 122.38%. Investors also watch the number of corporate investors in a company very closely, which is 120.79% institutions for Syndax Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at SNDX for having 7.91 million shares of worth $162.33 million. And as of 2024-06-30, it was holding 9.2721 of the company’s outstanding shares.

The second largest institutional holder is WELLINGTON MANAGEMENT GROUP LLP, which was holding about 7.34 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6063 of outstanding shares, having a total worth of $150.67 million.

On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 2.99 shares of worth $27.87 million or 3.47% of the total outstanding shares. The later fund manager was in possession of 2.55 shares on Mar 31, 2025 , making its stake of worth around $23.81 million in the company or a holder of 2.97% of company’s stock.